[go: up one dir, main page]

WO2012140636A1 - Formulation probiotique - Google Patents

Formulation probiotique Download PDF

Info

Publication number
WO2012140636A1
WO2012140636A1 PCT/IE2012/000017 IE2012000017W WO2012140636A1 WO 2012140636 A1 WO2012140636 A1 WO 2012140636A1 IE 2012000017 W IE2012000017 W IE 2012000017W WO 2012140636 A1 WO2012140636 A1 WO 2012140636A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
infantis
cells
foxp3
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2012/000017
Other languages
English (en)
Inventor
Liam O'mahony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PrecisionBiotics Group Ltd
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of WO2012140636A1 publication Critical patent/WO2012140636A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to retinoic acid and immune regulation.
  • mucosal immune system must correctly discriminate between harmful microbes and commensal microbes in order to ensure protective immunity and tolerance respectively.
  • a characteristic feature of mucosal tolerance is the induction and expansion of Foxp3+ T regulatory cells which limit excessive pro-inflammatory responses 4"5 .
  • Specific microbes present within the gastrointestinal tract which selectively promote Foxp3+ polarization within the mucosa of mice have been identified 6"10 .
  • both myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) are in close contact with microbes and are responsible for presenting microbial and dietary antigens to the adaptive immune system thereby influencing polarization of the adaptive response via cytokine and metabolite production 14"1 8 .
  • mDCs myeloid dendritic cells
  • pDCs plasmacytoid dendritic cells
  • TLR-2 recognition of zymosan results in the secretion of retinoic acid and IL-10 leading to Foxp3+ induction while dectin-1 activation by zymosan leads to IL-23 secretion and Thl 7 induction 20 .
  • TLR-2 activation was demonstrated to inhibit TLR-3 associated inflammatory responses within the skin in a TRAF-1 -dependent mechanism 21 .
  • DC subsets may utilize different molecular mechanisms to cooperate in the induction of T regulatory cells 22 ' 23 .
  • the invention provides a formulation comprising Bifidobacteria infantis 35624 in an amount to induce the expression of retinaldehyde dehydrogenase (RALDH) and a substrate that provides a source of retinal which is metabolised to all-trans retinoic acid by RALDH.
  • RALDH retinaldehyde dehydrogenase
  • the substrate may be retinal. In a different embodiment, the substrate may be retinol. Alternatively, the substrate may be retinyl acetate, retinyl palmitate, retinol acetate or retinol palmitate.
  • the formulation may comprise from about l xl O 4 to about lxl O 12 colony forming units (cfu) Bifidobacteria infantis 35624 per gram of formulation.
  • the formulation may comprise at least l lO 9 colony forming units (cfu) Bifidobacteria infantis 35624 per gram of formulation.
  • Bifidobacteria infantis 35624 may be in the form of viable cells in the formulation. Alternatively, Bifidobacteria infantis 35624 may be in the form of non-viable cells.
  • Bifidobacteria infantis 35624 may induce the expression of RALDH2.
  • the formulation may comprise one or more additional components selected from: lipids, fats, fatty acids, proteins, carbohydrate sources, vitamins, minerals, emulsifiers, stabilisers and prebiotics.
  • the formulation may be in a form suitable for enteral administration.
  • the formulation described herein may be used to maintain a normal structure and function of the skin and mucous membranes.
  • the formulation described herein may be used in the prophylaxis and/or treatment of a mucosal inflammatory condition.
  • the mucosal inflammatory condition may be associated with gastrointestinal health such as diarrhoea, inflammatory bowel disease or irritable bowel syndrome; respiratory inflammatory disorders such as asthma and broncho-pulmonary dysplasia; disorders of the eyes such as uveitis; disorders of the nose such as rhinitis or allergy; or cancer associated with mucosal surfaces such as lung or the gastrointestinal tract.
  • the formulation described herein may be used in the prophylaxis and/or treatment of one or more inflammatory disorder selected from the group comprising: asthma, gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis, or post infection colitis, gastrointestinal cancer(s), systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer due to undesirable inflammatory activity, diarrhoeal disease due to undesirable inflammatory activity, such as Clostridium difficile associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea, diarrhoeal disease due to an infectious agent, such as E.coli.
  • gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis, or post infection colitis
  • gastrointestinal cancer(s) systemic disease such as rheumatoid arthritis,
  • the formulation described herein may be used in the prophylaxis and/or treatment of vitamin A deficiency.
  • the invention also provides a method of maintaining normal structure and function of the skin and mucous membranes comprising the step of administering an effective amount of formulation described herein to a subject.
  • the invention also provides a method of prophylaxis and/or treatment of a mucosal inflammatory condition comprising the step of administering an effective amount of formulation described herein to a subject.
  • the mucosal inflammatory condition may be associated with gastrointestinal health such as diarrhoea, inflammatory bowel disease or irritable bowel syndrome; respiratory inflammatory disorders such as asthma and broncho-pulmonary dysplasia; disorders of the eyes such as uveitis; disorders of the nose such as rhinitis or allergy; or cancer associated with mucosal surfaces such as lung or the gastrointestinal tract.
  • the invention also provides a method of prophylaxis and/or treatment of one or more inflammatory disorder selected from the group comprising: asthma, gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis, or post infection colitis, gastrointestinal cancer(s), systemic disease such as rheumatoid arthritis, autoimmune disorders, cancer due to undesirable inflammatory activity, diarrhoeal disease due to undesirable inflammatory activity, such as Clostridium difficile associated diarrhoea, Rotavirus associated diarrhoea or post infective diarrhoea, diarrhoeal disease due to an infectious agent, such as E.coli comprising the step of administering an effective amount of formulation described herein to a subject.
  • gastrointestinal inflammatory activity such as inflammatory bowel disease eg. Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis, or post infection colitis
  • the invention also provides a method of prophylaxis and/or treatment of vitamin A deficiency comprising the step of administering an effective amount of formulation described herein to a subject.
  • B. infantis 35624 induces the immune-regulatory enzyme RALDH2 in dendritic cells and the product of this enzyme, retinoic acid, was essential for the induction of regulatory T cells.
  • a formulation which combines the substrate, i.e vitamin A or its derivatives, with a bacterial strain that induces expression of the enzyme responsible for substrate conversion will ensure the optimal conversion of the substrate to its immunologically active product. This formulation will provide a profound therapeutic benefit in patients suffering from inflammatory disorders.
  • vitamin A deficiency is estimated to affect approximately one third of children under the age of five around the world. It is estimated to claim the lives of 670,000 children under five annually. Deficiency of vitamin A severely affects vision and also reduces immunological defense and tolerance mechanisms.
  • Vitamin A a source of Vitamin A, a derivative of Vitamin A, and/or a source of a derivative of Vitamin A;
  • the Bifidobacterium comprises Bifidobacterium infantis 35624
  • the formulation comprises Bifidobacterium infantis 35624 with vitamin A. The formulation induces optimal retinoic acid production in vivo, thereby promoting immune regulatory functions and inhibiting inflammatory diseases.
  • the strain may be in the form of a biologically pure culture.
  • Bifidobacterium strains are in the form of viable cells.
  • Bifidobacterium strains are in the form of non-viable cells.
  • the formulation may be in the form of a food or a supplement.
  • the formulation includes another probiotic material.
  • the formulation includes a prebiotic material.
  • the formulation includes an ingestable carrier.
  • the ingestable carrier may be a pharmaceutically acceptable carrier such as a capsule, tablet or powder.
  • the ingestable carrier is a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.
  • the formulation of the invention further comprises a protein and/or peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, mineral and/or trace element.
  • the Bifidobacterium strain is present in the formulation at more than 10 6 cfu per gram of delivery system.
  • the formulation may include any one or more of an adjuvant, a bacterial component, a drug entity or a biological compound.
  • the invention provides a screening method for identifying immunoregulatory Bifidobacteria comprising the co-incubation of a test bacterium with mammalian cells and assaying retinoic acid production.
  • Fig 1. illustrates that human dendritic cells bind and internalise B. infantis 35624.
  • Myeloid and plasmacytoid dendritic cells (mDCs, pDCs) efficiently bind B. infantis as visualized by muitispectral flow cytometry imaging (A).
  • A muitispectral flow cytometry imaging
  • B is a conventional microscope image showing that myeloid dendritic cells bind and internalize B. infantis.
  • B. infantis is carboxy fluorescein diacetate succinimidyl ester (CFSE) labeled (white arrow) while CD1 lc+ cells are Pc5 labelled (striped arrow) for the multispectral and flow cytometry analysis.
  • C is a flow cytometry plot confirming the binding of B.
  • D is a fluorescent image showing that internalization of B. infantis into lysosomes was identified using isotracker staining (arrows) after 16 hours co-incubation, internalized B. infantis cells were co-localised within MDDC activated lysozymes. Approximately 30% of the MDDC population internalize B. infantis.
  • E are plots showing that CD80 and CD86 are significantly upregulated on MDDCs when exposed to LPS (positive control) while B. infantis stimulates co-stimulatory molecule expression in a dose-dependent manner (representative data of 5 independent experiments);
  • FIG. 2. is a graph showing gene expression of the enzymes required for retinoic acid metabolism, RALDH1 , 2 & 3, quantified every 4 hours, until 24 hours, following B. infantis stimulation. RALDH2 rapidly increased in expression, peaking at 12 hours following stimulation. Retinoic acid production by dendritic cells is an important feature of mucosal immune health.
  • B are plots showing how the functional activity of RALDH was confirmed by conversion of a non-fluorescent substrate into a fluorescent product in MDDCs and mDCs exposed to B. infantis for 24 hours. The RALDH inhibitor DEAB blocked the conversion of the substrate. (All experiments were repeated independently at least 4 times);
  • Fig. 3. are plots showing that direct contact between MDDCs and B. infantis is associated with retinoic acid production.
  • B. infantis was labeled with PKH26, incubated with MDDCs for 24 hours at which time retinoic acid induction was assessed.
  • RALDH induction is enriched in the MDDC population which have bound high numbers of B. infantis. (This data is representative of 3 independent experiments);
  • Fig. 4. are flow cytometry plots showing that B. infantis stimulated MDDCs or mDCs induce CD25+Foxp3+ T cells which was associated with increased secretion of IL-10, but not IL-12p70.
  • C is a graph showing that T-bet was induced in response to other Bifidobacteria but not B. infantis 35624.
  • D are plots showing that inhibition of retinoic acid production or retinoic acid signaling blocked the induction of Foxp3+ cells by B.
  • D are plots showing that Foxp3 expression was significantly increased in CD25 high and CD25 intermediate CD4 T cells following B. infantis treatment. (*p ⁇ 0.05 versus placebo group; *i p ⁇ 0.01 versus pre-treatment (Week 0));
  • (D) is a graph showing the quantification of ALDH1A2 gene expression (encoding the RALDH2 enzyme) every 6 hours, until 18 hours, following B. infantis stimulation of MDDCs, mDCs and pDCs.
  • (E) are plots showing the functional activity of RALDH as determined by detection of BODIPY- aminoacetate (BAA) positive MDDCs and mDCs, but not pDCs, exposed to B. infantis for 24 hours.
  • BAA BODIPY- aminoacetate
  • the RALDH inhibitor DEAB blocked the conversion of the substrate.
  • (F) is a graph showing that gene expression of the metabolic enzyme IDO was observed in MDDCs, mDCs and pDC. (For D-F, all experiments were repeated independently for at least 4 donors);
  • FIG. 9. are plots showing B. infantis labeled with P H26, incubated with MDDCs for 24 hours at which time retinoic acid metabolism was assessed by detection of BODIPY- aminoacetate (BAA) positive MDDCs.
  • BAA BODIPY- aminoacetate
  • PKH26 positive MDDCs which have bound B. infantis and are labeled as B. infantis +ve
  • PKH26 negative MDDCs which have not bound B. infantis are labeled B. infantis -ve.
  • B is a plot showing that following gating of the B. infantis +ve and B. infantis -ve cells, RALDH enzyme activity is increased in the MDDCs, which have bound B. infantis. Unstimulated cells were not incubated with B. infantis.
  • C is a graph showing the induction of RALDH activity by B. infantis is dose dependent, with an optimal bacterial :MDDC cell ratio of 10: 1. (Results from two independent donors are illustrated);
  • Blocking of TLR-2 significantly reduced IL-10 secretion, which was accompanied by a significant increase in IL-12p70 and TNF-a secretion.
  • A are graphs showing that blocking of DC-SIGN had no impact on IL-10 or IL-12p70 secretion but did result in increased TNF-a secretion. 5.
  • (B) are graphs showing that blocking of TLR-2 or DC-SIGN significantly reduced IL-10 secretion, which was accompanied by a significant increase in TNF-a secretion.
  • (D) is a graph showing that pre-incubation of pDC with blocking TLR-9-specific ODNs significantly reduced pDC secretion of IL-10 in response to 5. infantis stimulation. IL-10, IDO and IFN-a gene expression were quantified in pDCs following stimulation with CpG or 5. infantis for 0, 6, 12 or 18 hours (E).
  • Fig. 12. are graphs showing that HEK-293 cells, which do not express TLR-2 (TLR-2Neg), remained unstimulated by B. infantis.
  • HEK-293 cells, which expressed TLR-2 (TLR-2Pos) were able to respond to B. infantis as demonstrated by NF- ⁇ activation and IL-8 secretion.
  • Anti- TLR-2 blocking antibody significantly reduced both NF- ⁇ activation and IL-8 secretion (results are shown as the mean of 3 independent experiments). Cells were stimulated with Pam3CSK4 as the positive control TLR-2 ligand.
  • Fig. 13 are graphs showing that TLR-2 and TLR-6, but not TLR-1 , are required for optimal NF- KB and IL10 induction.
  • (A) are plots showing that blocking of either TLR-2 or DC-SIGN significantly attenuated RALDH induction by B. infantis-stimulated MDDCs.
  • (C) is a graph showing that stimulation of MDDCs with TLR-2 (Pam3CSK4) or DC-SIGN (ManLam) specific ligands induced retinoic acid metabolism, while TLR-4 (LPS) or TLR-5 (flagellin) stimulation did not. (*p ⁇ 0.05 versus isotype control antibody);
  • FIG. 15. is a graph showing B. infantis stimulated MDDCs co-cultured with autologous CD4+ T cells for five, seven or nine days. T cells were co-cultured with B. infantis stimulated MDDCs alone or were re-stimulated with anti-CD2/CD3/CD28 antibodies for two days prior to analysis. Induction of Foxp3 by unstimulated MDDCs was also assessed under both culture conditions and at each timepoint. The data was normalized by subtracting the unstimulated MDDC-T cell Foxp3+ levels from B. infantis stimulated MDDC-T cell at each timepoint with or without re-stimulation. Peak induction of Foxp3+ lymphocytes occurred at seven days co-culture with B. infantis stimulated MDDCs.
  • A CD25+Foxp3+ T cells
  • the flow cytometry density plots illustrated are from anti- CD2/CD3/CD28 restimulated T cell cultures.
  • FIG. 18 is a graph showing the increased % cells, from mesenteric lymph nodes, actively metabolising retinoic acid (CD1 l b+CDl l c+CD103+RALDH+ but CD3 and CD 19 negative) following administration of B.
  • FIG. 19 is a graph showing the increased % Tregs cells (CD3+CD4+CD25+Foxp3+), from mesenteric lymph nodes, following administration of B. infantis 35624 (relative to placebo; p ⁇ 0.05, 1 way ANOVA), which is reversed by co-administration of the RALDH inhibitor Citral;
  • Fig. 20. are graphs showing the decreased % lamina limbal cells producing pro-inflammatory cytokines (CD3+CD4+IL-17+ or IFN-g+) following administration of B. infantis 35624 (relative to placebo; p ⁇ 0.05, 1 way ANOVA), which is reversed by co-administration of the RALDH inhibitor Citral;
  • Fig. 21 are graphs showing the influx of alpha4/beta7+ lymphocytes into from mesenteric lymph nodes and lamina intestinal following DSS induction of colitis, which is blocked by B. infantis administration. This effect is reversed by administration of the RALDH inhibitor Citral; and Fig.
  • a deposit of Bifidobacterium longum biotype infantis strain UCC 35624 was made at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA, Scotland, UK on January 13, 1999 and accorded the accession number NCIMB 41003.
  • NCIMB National Collections of Industrial and Marine Bacteria Limited
  • Bifidobacterium infantis 35624 (B. infantis) is a commensal microbe that was originally isolated from the human gastrointestinal mucosa. Bifidobacterium infantis 35624 is sold by Procter & Gamble Co. under the trademark Bifantis. Bifidobacterium infantis 35624 is described in EP 1 141 235 B l, US 7, 195,906, WO 2010/003803 and Brenner et al 44 .
  • B. infantis 35624 has been identified as a probiotic which can limit inflammatory disease, both in mice and humans, we examined the mechanisms underpinning the immune regulatory nature of this organism 6 ' 24"30 .
  • human dendritic cells exposed to B. infantis 35624 induced the conversion of na ' ive T cells into regulatory T cells in a retinoic acid-dependent manner.
  • the induction of vitamin A metabolizing enzymes by B. infantis 35624 is an essential molecular step in its ability to suppress proinflammatory disorders.
  • humans that consume B. infantis have significantly elevated IL-10 responses and Foxp3 expression following in vivo exposure, supporting our in vitro observations.
  • Retinoic acid was required for DC induction of Foxp3+ T cells.
  • Induction of Foxp3+ T regulatory cells is a pivotal feature of mucosal immune tolerance.
  • oral feeding of healthy human volunteers with B. infantis results in increased numbers of Foxp3+ CD4+ T cells within peripheral blood, which is associated with enhanced secretion of IL-10 following stimulation.
  • our in vitro data supports the hypothesis that DCs are responsible for the induction of Foxp3+ cells. Both myeloid and plasmacytoid DC subsets play a role, but recognize B. infantis via different PRRs.
  • Induction of Foxp3+ T cells by DDCs and mDCs involves TLR-2, DC-SIGN and retinoic acid metabolism.
  • retinoic acid generation from vitamin A occurs in intestinal epithelial cells and specialized dendritic cell subsets resulting in the conversion of naive T cells into Foxp3+ T regulatory cells 33 .
  • the gut-specific factors which promote vitamin A metabolism have been poorly described.
  • the presence of certain bacterial strains within the gastrointestinal tract may provide the necessary signals to gut-associated lymphoid tissue for the induction of enzymes, such as RALDH2, which are required for maintaining intestinal homeostasis in a milieu of exogenous antigenic challenge.
  • enzymes such as RALDH2
  • tryptophan metabolism but not retinoic acid metabolism, is required for the. induction of Foxp3+ CD4 T cells by pDCs upon B. infantis exposure.
  • microbiota-derived short-chain fatty acids suggest that we may have previously under estimated the importance of the relationship between diet and the microbiota 34 .
  • SCFA microbiota-derived short-chain fatty acids
  • TLR-2 KO animals are more sensitive to dextran sodium sulphate- induced colitis, while TLR-2 gene variants are associated with disease phenotype in IBD patients. Indeed, TLR-2 has been demonstrated to promote Foxp3 expression in response to intestinal microbes in murine models 37 ' 38 .
  • Our results show that inhibition of human mDC TLR- 2/6 activation resulted in suppression of IL- 10 secretion and Foxp3 induction, while enhancing secretion of IL-12p70 and TNF-cc following B. infantis exposure.
  • DC-SIGN activation by B. infantis is required for full RALDH activity and blocking DC-SIGN results in significantly fewer Foxp3+ CD4+ T cells.
  • TLR-9 is required for pDC secretion of IL-10 in response to B. infantis.
  • CpG stimulation of pDCs resulted in enhanced IFN-cc gene expression, which was not observed with B. infantis stimulation, suggesting that other molecular pathways distinct from those induced solely by TLR-9 are involved in the pDC response to this bacterium.
  • Appropriate PRR activation in vivo may promote immune homeostatic mechanisms, which limit the activation of pro-inflammatory responses and protect mucosal tissue from injury.
  • the involvement of multiple P Rs suggests that multiple bacterial components including lipoteichoic acids (TLR-2), polysaccharides (DC-SIGN) and DNA (TLR-9) are all important for optimal induction of the immune regulatory program in vivo.
  • TLR-2 lipoteichoic acids
  • DC-SIGN polysaccharides
  • TLR-9 DNA
  • a commensal microbe that expresses all of these regulatory factors may be more efficient in the local induction of Foxp3+ cells compared to a commensal bacterium that only expresses one or two regulatory factors.
  • mDCs and pDCs are present within the gastrointestinal tract at relatively high numbers compared to the peripheral blood. .
  • pDCs are numerically dominant within the lamina limbal and Peyer's patches, while mDCs dominate mesenteric lymph nodes 39 .
  • pDCs have been shown to be essential for the induction and maintenance of oral tolerance as systemic depletion of pDCs prevents tolerance induction to fed antigen, while adoptive transfer of oral antigen-loaded liver pDCs induced antigen-specific suppression of CD4 and CD8 T cell responses 40 . It is likely that mDCs and pDCs will also cooperate in the induction of tolerance to commensal microbes other than B. infantis, but our data suggests that not all Bifidobacteria induce the same pDC and mDC response.
  • B. infantis 35624 has been shown to protect against inflammatory disease in a number of murine models (including colitis, arthritis, respiratory allergy and infectious models).
  • murine models including colitis, arthritis, respiratory allergy and infectious models.
  • oral administration of this bacterium results in elevated IL-10 responses and Foxp3 expression in CD4+ T cells and we describe the potential cellular mechanisms underpinning this regulatory response.
  • Manipulation of T regulatory cell numbers or functions is an exciting therapeutic target in a wide range of inflammatory diseases 4 ' ' 42 .
  • PBMCs Peripheral blood mononuclear cells
  • PBMCs Peripheral blood mononuclear cells
  • Freshly isolated PBMCs were stained with monoclonal antibodies to CD4- PerCP, CD25-APC, ICOS-PE, CTLA-4-PE and Foxp3-Alexa Fluor 488 (eBioscience, San Diego, CA, USA).
  • Duplicate samples were evaluated using a FACSCalibur (Becton Dickinson) and analysis was carried out using the BD CellQuest software.
  • 1 x 10 6 cells/mL PBMCs were stimulated with anti-CD3 ⁇ 5 ⁇ igl ⁇ ) and anti-CD28 ⁇ 5 aglm ⁇ ) antibodies for 48 hours.
  • PBMC supernatants were analysed for cytokine levels simultaneously using the MesoScale Discovery (MSD) multiplex platform.
  • MSD MesoScale Discovery
  • the dried powder active was manufactured to a cGMP standard at Chr Hansen A/S, Denmark.
  • the active was blended with maltodextrin and magnesium stearate and packaged in 5g sachets and stored at 4 degrees Celius.
  • Active ingredient Bifidobacterium Infantis 35624 at approx. 4xl0 9 cfu/sachet (the target dosage of Bifidobacterium Infantis 35624 was l x 10 9 cfu per day, each sachet contained approx. 4x10 9 cfu Bifidobacterium Infantis 35624 to allow for loss of numbers on storage).
  • a sachet Prior to consumption, a sachet was opened and the contents added to a glass of milk (50-100mls) as part of a meal at breakfast time and consumed within 15 minutes on a daily basis each morning for 8 weeks. Subjects consumed lxl 0 9 to 4x10 9 cfu Bifidobacterium Infantis 35624 per day.
  • the dried powder active was manufactured to a cGMP standard at Chr Hansen A/S, Denmark.
  • the active was blended by Bifodan AS, Denmark and packaged in lg sachets and stored at 4 degrees Celius.
  • Active ingredient Bifidobacterium Infantis 35624 at approx. 4x10 9 cfu/sachet (the target dosage of Bifidobacterium Infantis 35624 was l x 10 9 cfu per day, each sachet contained approx. 4x10 9 cfu Bifidobacterium Infantis 35624 to allow for loss of numbers on storage).
  • a sachet Prior to consumption, a sachet was opened and the contents added to a glass of milk (50-100mls) as part of a meal at breakfast time and consumed within 15 minutes on a daily basis each morning for 8 weeks. Subjects consumed lxl O 9 to 4xl0 9 cfu Bifidobacterium Infantis 35624 per day.
  • Dendritic cell experiments were performed using cells isolated from naive (i.e. non-B. infantis fed) healthy volunteers.
  • Human peripheral blood monocytes were obtained using CD 14+ positive isolation with the MACS system (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were cultured in cRPMI media (Invitrogen, Carlsbad, USA) with 1,000 U/ml IL-4 (Novartis, Basel, Switzerland) and 1 ,000 U/ml GM-CSF (PeproTech, London, UK) for 5 days in order to generate MDDCs.
  • Peripheral blood mDCs were isolated following CD3, CD 14 and CD 19 depletion and CDlc positive selection with the MACS system.
  • Peripheral blood pDCs were positively enriched using CD304 isolation with the MACS system. In addition, flow cytometric sorting with anti-CD123 FITC (Miltenyi Biotec) yielded a highly purified pDC population. Peripheral blood CD4+ T cells were isolated by negative selection with the MACS system. MDDCs, mDCs and pDCs were routinely cultured in cRPMI medium and stimulated with bacterial strains or remained unstimulated. For blocking experiments, dendritic cells were pre- incubated for 30 minutes with control oligonucleotide GCTAGATGTTAGCGT (SEQ ID NO.
  • TLR9 antagonist oligonucleotide TTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG SEQ ID No. 2
  • anti-TLR2 gift from C. Kirschning, Kunststoff, Germany
  • anti-DC-SIGN anti-DC-SIGN
  • IgG2B control antibody R&D Systems Europe, Abingdon, England
  • infantis localization within activated lysosomes was determined by staining MDDCs with Lysotracker red DND-99 (Invitrogen) and DAPI in ProLong Gold antifade reagent (Invitrogen). Slides were analyzed by confocal microscopy. RALPH assessment
  • MDDCs, mDCs and pDCs were stimulated with bacteria (with or without inhibitors) for 16-24 hours in cRPMI.
  • RALDH activity was determined using the ALDEFLOUR kit (Aldagen, Durham, USA) and positive cells were visualized by flow cytometry.
  • MDDCs were incubated with PKH26 stained B. infantis in order to co-localise bacterial binding and RALDH induction.
  • HEK-Blue hTLR-2 cells and HEK-Blue Null l cells were stimulated with B. infantis for 24 hours. Both cell lines express the NF-KB-inducible secreted embryonic alkaline phosphatase (SEAP) reporter.
  • SEAP NF-KB-inducible secreted embryonic alkaline phosphatase
  • the TLR-2 ligand Pam3CSK4 (2 ⁇ g/ml, Calbiochem, Merck GaA, Darmstadt, Germany) was used as a positive control.
  • Dendritic cells were stimulated for 4 hours with test bacterial strains and co-cultured with autologous CD4+ T cells at a 1 :40 ratio (mDCs) or a 1 :20 ratio (MDDCs and pDCs) in AIM-V media (Invitrogen, Carlsbad, USA). After 5 days, cells were re-stimulated with anti-CD28 (generated in house), anti-CD3 (Orthoclone OKT3, Janssen-Cilag) and anti-CD2 (Sanquin, Amsterdam, Netherlands). Two days later lymphocytes were permeabilised and stained for CD4, CD25 and Foxp3 (eBioscience San Diego, CA, USA). Citral (Sigma- Aldrich, St.
  • retinal dehydrogenases retinaldehyde dehydrogenases
  • RALDH enzymes retinaldehyde dehydrogenases
  • retinoic acid (all-trans- retinoic acid) regulates gene transcription by binding to nuclear receptors known as retinoic acid receptors (RARs) which are bound to DNA as heterodimers with retinoid "X" receptors (RXRs).
  • RARs nuclear receptors
  • RXRs retinoic acid receptors
  • the RAR-RXR heterodimer recognizes retinoic acid response elements (RAREs) on the DNA whereas the RXR-RXR homodimer recognizes retinoid "X" response elements (RXREs) on the DNA.
  • RAREs retinoic acid response elements
  • RXREs retinoid "X" response elements
  • the receptors undergo a conformational change that causes co-repressors to dissociate from the receptors.
  • Coactivators can then bind to the receptor complex, which may help to loosen the chromatin structure from the histones or may interact with the transcriptional machinery. This response can upregulate
  • B. infantis induced the expression of RALDH2 in MDDCs as assessed by RT-PCR (Figure 2A).
  • the functional activity of RALDH2 was confirmed in MDDCs and mDCs by flow cytometry ( Figure 2B). Inhibition of RALDH activity with DEAB completely blocked the conversion of the substrate.
  • MDDCs which had bound B. infantis expressed greater RALDH2 activity compared to MDDCs that had not captured B. infantis ( Figure 3).
  • B. infantis induced expression of the ALDH1A2 gene, which encodes for the enzyme retinaldehyde dehydrogenase 2 (RALDH2), in MDDCs and mDCs but not pDCs ( Figure 7D).
  • ALDH1A2 which encodes for the enzyme retinaldehyde dehydrogenase 2 (RALDH2)
  • MDDCs express high levels of Dectin-1 , however no significant differences in cytokine production were observed for IL-10 (1 ,626 +/- 453 pg/ml compared to 1,522 +/- 418 pg/ml) or IL-12p70 (12.5 +/- 4.8 pg/ml compared to 1 1.9 +/- 4.1 pg/ml) secretion with Dectin-1 inhibition.
  • Blockade of MDDC TLR-2 resulted in significantly decreased secretion of IL-10 and significantly increased secretion of IL- 12p70 and TNF-a (Figure 1 1 A). Inhibition of MDDC DC-SIGN did not significantly alter IL- 10 or IL-12 secretion although TNF-a secretion was significantly increased ( Figure 1 1 A). Blockade of mDC TLR-2 or DC-SIGN resulted in significantly reduced IL-10 secretion associated with increased secretion of TNF-a ( Figure 1 I B). In order to confirm that TLR-2 induced an intracellular signaling cascade in response to B. infantis, we examined HE -293 cells, which were engineered to express TLR-2.
  • HE -293 TL "2+ cells responded to B. infantis as demonstrated by an increase in NF- ⁇ activation and IL-8 secretion ( Figure 12). In contrast, NF-KB activation and IL-8 secretion did not increase over baseline levels in HEK TLR 2" cells. In addition, pre-incubation of HEK-293 TLR"2+ cells with anti-TLR-2 blocking antibody significantly reduced NF-KB activation and IL-8 secretion in response to B. infantis. TLR-2 can form heterodimers with either TLR-1 or TLR-6. Blocking TLR-1 had no effect on B.
  • TLR-6 had a partial effect but not as significant as TLR-2 blockade ( Figure 13).
  • the combination of anti-TLR-2 and anti-TLR-6 antibodies was the most effective in the inhibition of HEK-293 NF- ⁇ activation and MDDC IL- 10 secretion.
  • TLR-2 was expressed by pDCs at a very low level and blocking experiments did not alter the pDC IL-10 response to B. infantis ( Figure 1 1 C), while IL-12p70 was not detected.
  • blockade of TLR-9 with an inhibitory oligonucleotide abolished the secretion of IL- 10 by pDCs in response to B.
  • Example 5 Feeding of healthy human volunteers with B. infantis is associated with induction of IL-10 and Foxp3 in vivo
  • the gastrointestinal micro-environment has been previously described to favour the induction of regulatory lymphocytes.
  • retinoic acid generation from vitamin A occurs in intestinal epithelial cells and specialized dendritic cell subsets resulting in the polarization of B cell immunoglobulin synthesis, induction of gut homing receptors on lymphocytes and conversion of na ' ive T cells into Foxp3+ T regulatory cells.
  • the gut-specific factors which promote vitamin A metabolism are poorly described.
  • B. infantis 35624 upregulates the retinoic acid metabolizing enzyme RALDH2 in myeloid dendritic cells.
  • the retinoic acid response is functional as inhibition of retinoic acid production or retinoic acid signaling blocks the induction of Foxp3+ T cells.
  • the presence of certain bacterial strains within the gastrointestinal tract may provide the necessary signals to gut associated lymphoid tissue for the induction of enzymes, such as RALDH2, which are required for maintaining intestinal homeostasis in the context of multiple foreign, non-self, antigens.
  • enzymes such as RALDH2
  • this molecular mechanism links nutrition, the gastrointestinal microbiota and regulation of intestinal immune responses as the consumption of adequate vitamin A levels in the diet and the presence of RALDH2-inducing microbiota could result in the optimal local induction of Foxp3+ regulatory T cells.
  • PBMCs Peripheral blood mononuclear cells
  • Example 6 In-vivo studies demonstrate the upregulation of retinoic acid metabolism, by B. infantis 35624, within the gut mucosa
  • lamina limbal fibroblasts were isolated as single cell suspensions. These cells were then stained for dendritic cell markers, and flow cytometry performed to quantify retinoic acid metabolising cells (CD1 l b+CDl l c+CD103+RALDH+ but CD3 and CD19 negative), Tregs (CD3+CD4+CD25+Foxp3+), intracellular cytokines (CD3+CD4+IL- 1 7+ or IFN-g+ or IL-4+).
  • Figures 18 and 19 show the results for RALDH+ cells and T Regs in mesenteric lymph nodes, while Figure 20 shows the results of intracellular cytokines for lamina limbal cells.
  • Example 7 In-vivo studies demonstrate the influx of alpha4/beta7+ lymphocytes producing pro- inflammatory cytokines, is blocked by B. infantis 35624 and is dependent on retinoic acid metabolism.
  • B. infantis 35624 has been shown to induce retinoic metabolism in human myeloid dendritic cells in in vitro models. However, the in vivo relevance of these findings is currently unknown. These murine studies of colitis were designed to demonstrate that the effect of B. infantis 35624 is dependent on retinoic acid metabolism.
  • B. infantis 35624 dried powder active was manufactured by Chr Hansen A/S, Denmark and resuspended in the drinking water before use; approximately l -2xl 0 9 cfu per day.
  • Half of the animals in each group were also administered Citral daily (2mg per mouse i.p. injection).
  • Groups 1 (B. infantis 35624) and 2 (B. infantis 35624 + Citral) were euthanized after the feeding period and immunological measurements performed. Colitis was induced in groups 3 (B. infantis 35624 + colitis), 4 (B.
  • Figure 21 shows the results for CD4+ alpha4/beta7+ cells in mesenteric lymph nodes and for lamina propria cells
  • Figure 22 shows the results for intracellular cytokines for lamina propria cells.
  • DSS-induced colitis The data from this well recognised animal model of inflammation confirms observations from in-vitro studies. DSS-induced colitis is associated with an influx of inflammatory cells (CD4+ alpha4/beta7+ lymphocytes) and an increased production of intracellular pro-inflammatory cytokines (CD4+IL- 17+ or IFN-g+).
  • Administration of B. infantis. 35624 reversed these characteristic of inflammation ( Figures 21 and 22). In each case, the effect of B. infantis 35624 could be reversed using a selective inhibitor of RALDH (Citral) demonstrating the causal link between B. infantis 35624, RALDH induction and beneficial immune-modulation.
  • a composition or formulation of B. infantis and a substrate that provides a source of retinal can be administered by means known to those skilled in the art.
  • the form of administration of the composition or formulation is not critical as long as an effective amount of the composition or formulation is administered.
  • the composition or formulation may for example be administered enterally through or within the gastrointestinal or digestive tract. Enteral administration includes oral feeding, intragastric feeding, transpyloric administration or any other introduction into the digestive tract.
  • the composition or formulation may be administered via tablet, pills, encapsulations, caplets, gelcaps, capsules, oil drops, sachets, liquids, liquid concentrates, powders, elixirs, solutions, suspensions, emulsions, lozenges, beads, and combinations thereof.
  • the composition or formulation may be provided in a dissolvable form (such as a powder or tablet) to be added to a food or drink by the end user prior to consumption.
  • the composition or formulation may be added to a food or drink product such as dairy products (for example yogurt, cheese, milk, milk based drinks and the like) fruit juice, fruit-based drinks, milk powder (including infant and toddler formulations), beverages and the like.
  • the composition or formulation may be supplemented into a formulation for children or infants.
  • infant means a postnatal human that is less than about 1 year old.
  • child means a human in the age range of about 1 and 12 years old. In certain embodiments, a child is in the age range of about 1 and 6 years old. In other embodiments, a child is in the age range of about 7 and 12 years old.
  • the composition or formulation may be supplemented into a product for example an infant's nutritional product, such as an infant formula or a human milk fortifier.
  • infant formula means a composition that satisfies the nutrient requirements of an infant by being a substitute for human milk.
  • human milk fortifier means a composition which can be added to human milk to enhance the nutritional value of the human milk.
  • the composition is an acidified product (as required by certain medical food regulations).
  • the nutritional product may be a product for a full-term infant, a preterm infant, a low-birth-weight infant, or a very-low-birth-weight infant.
  • preterm or preterm infant may include low-birth-weight infants or very-low-birth weight infants.
  • Low- birth-weight infants are those born from about 32 to about 37 weeks of gestation or weighing from about 3.25 to about 5.5 pounds at birth.
  • Very-low-birth-weight infants are those born before about 32 weeks of gestation or weighing less than about 3.25 pounds at birth.
  • preterm infants may include infants born before about 37 weeks gestation and/or those weighing less than about 5.5 pounds at birth.
  • the composition or formulation may provide minimal, partial, or total nutritional support.
  • the composition or formulation may be nutritional supplements or meal replacements.
  • the composition or formulation may be administered in conjunction with a food or nutritional composition for example, the composition or formulation can either be intermixed with the food or nutritional composition prior to ingestion by the subject or can be administered to the subject either before or after ingestion of a food or nutritional composition.
  • the composition or formulation may be administered to preterm infants receiving infant formula, breast milk, a human milk fortifier, or combinations thereof.
  • the composition or formulation may, but need not, be nutritionally complete.
  • nutritionally complete it is meant that the composition contains adequate nutrients to sustain healthy human life for extended periods.
  • the formulation may be nutritionally complete and contain suitable types and amounts of lipid, carbohydrate, protein, vitamins and minerals.
  • Commercially available infant formulas and other formulations for example, Enfamil®, Enfamil® Premature Formula, Enfamil® with Iron, Lactofree®, Nutramigen®, Pregestimil®, and ProSobee® (available from Mead Johnson & Company, Evansville, Ind., U.S.A.) may be supplemented with suitable levels of a composition or formulation describe herein.
  • the composition or formulation comprises a substrate that provides a source of retinal.
  • the quantity of the substrate in the composition or formulation should be sufficient to provide the recommended daily allowance (RDA) of vitamin A in the all-trans retinoic acid form to the end user.
  • Suitable substrates include retinal, retinol, retinyl acetate, retinyl palmitate, retinol acetate, retinol palmitate, beta carotene, alpha carotene, gamma carotene or beta cryptoxanthin.
  • B. infantis 35624 is incorporated into the composition or formulation in an amount suitable to induce the expression of RALDH at a level that will metabolise a source of retinal to all-trans retinoic acid.
  • the amount of B. infantis 35624 incorporated into the composition or formulation may correspond to the range of from about l xlO 4 to about lxlO 12 colony forming units (cfu).
  • the amount of B. infantis 35624 incorporated into the composition or formulation may correspond to the range of from about l xl O 6 to about l xl O 9 colony forming units (cfu).
  • the amount of B. infantis 35624 incorporated into the composition or formulation may be at least lxl O 9 colony forming units (cfu).
  • the amount of B. infantis 35624 incorporated into the composition or formulation may be colony forming units (cfu) per gram composition or formulation or a total daily amount of colony forming units (cfu).
  • the composition or formulation may comprise additional components such as lipids, fats, fatty acids, proteins, carbohydrate sources, minerals, emulsifiers, stabilisers, and combinations thereof.
  • the amount of lipid or fat typically may vary from about 3 to about 7 g/100 kcal.
  • Lipid sources may be any known or used in the art, e.g., milk fat, egg yolk lipid, fish oil, vegetable oils such as palm oil, soybean oil, palmolein, palm oil, palm kernel oil, coconut oil, medium chain triglyceride oil, high oleic sunflower oil, olive oil, high oleic safflower oil, and esters of fatty acids.
  • the amount of protein typically may vary from about 1 to about 5 g/100 kcal.
  • Protein sources may be any known or used in the art, e.g., milk protein, non-fat milk solids, nonfat milk, whey protein, casein, soy protein, animal protein, cereal protein, vegetable protein, or combinations thereof.
  • the composition or formulation may contain proteins and/or peptides rich in glutamine/glutamate.
  • the protein source may be intact, partially hydrolyzed, or extensively hydrolyzed.
  • the protein source may be a combination of intact protein and hydrolyzed protein.
  • the protein source may be an isolate or a concentrate.
  • the composition or formulation may contain a nitrogen source, such as amino acids and/or protein, such that the total amount of amino acids or protein may be from about 1 g/100 kilocalories (kcal) to about 10 g/100 kcal of total composition, or from about 2 g/100 kcal to about 6 g/100 kcal.
  • the amount of lipid source per 100 kcal of total composition may be greater than 0 g up to about 6 g, for example about 0.5 g to about 5.5 g, or about 2 g to about 5.5 g; and the amount of non-fiber carbohydrate source per 100 kcal of total composition may be from about 5 g to about 20 g, such as from about 7.5 g to about 15 g.
  • the amount of vitamins and minerals in the nutritionally complete composition may be sufficient to meet 100% of the recommended daily allowance (RDA).
  • the composition or formulation may be protein-free.
  • a protein-free composition or formulation may contain a protein equivalent source that comprises 100% free amino acids.
  • carbohydrate typically may vary from about 8 to about 12 g/100 kcal.
  • Carbohydrate sources may be any known or used in the art, e.g., lactose, fructose, glucose, corn syrup, corn syrup solids, maltodextrins, sucrose, starch, rice syrup solids, rice starch, modified corn starch, modified tapioca starch, rice flour, soy flour, and combinations thereof.
  • composition or formulation may optionally include one or more of the following vitamins or derivatives thereof, including, but not limited to, biotin, vitamin B l , thiamin, thiamin pyrophosphate, vitamin B2, riboflavin, flavin mononucleoride, flavin adenine dinucleotide, pyridoxine hydrochloride, thiamin mononitrate, folic acid, vitamin B3, niacin, nicotinic acid, nicotinamide, niacinamide, nicotinamide adenine dinucleotide, tryptophan, biotin, pantothenic acid, vitamin B6, vitamin B 12, cobalamin, methylcobalamin, deoxyadenosylcobalamin, cyanocobalamin, calcium pantothenate, pantothenic acid, vitamin C, ascorbic acid, vitamin D, vitamin D3, calciferol, cholecalciferol, dihydroxy vitamin D, 1 ,25
  • composition or formulation may optionally include one or more of the following minerals or derivatives thereof, including, but not limited to, phosphorus, potassium, sulfur, sodium, docusate sodium, chloride, manganese, magnesium, magnesium stearate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium sulfate, copper, cupric sulfate, iodide, boron, zinc, zinc oxide, chromium, molybdenum, iron, carbonyl iron, ferric iron, ferrous fumarate, polysaccharide iron, fluoride, selenium, molybdenum, calcium phosphate or acetate, potassium phosphate, magnesium sulfate or oxide, sodium chloride, potassium chloride or acetate, ferric orthophosphate, alpha-tocopheryl acetate, zinc sulfate or oxide, copper gluconate, chromium chloride or picolonate, potassium iodide, sodium selenate, sodium molybdate, phylloquinon
  • composition or formulation also may contain emulsifiers and stabilizers such as soy lecithin, carrageenan, and combinations thereof.
  • emulsifiers and stabilizers such as soy lecithin, carrageenan, and combinations thereof.
  • the composition or formulation may optionally contain other substances that may have a beneficial effect such as lactoferrin, nucleotides, nucleosides, immunoglobulins, and combinations thereof.
  • the composition or formulation may contain one or more prebiotics.
  • prebiotic means a non-digestible food ingredient that stimulates the growth and/or activity of probiotics. Any prebiotic known in the art will be acceptable provided it achieves the desired result. Suitable prebiotics include oligosaccharides, polysaccharides, and other prebiotics that contain fructose, xylose, soya, galactose, glucose and mannose.
  • Suitable prebiotics may also include lactulose, gluco-oligosaccharide, inulin, polydextrose, galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide, soybean oligosaccharides, lactosucrose, xylo-oligosacchairde, and gentio-oligosaccharides.
  • the composition or formulation may contain other active agents such as long chain polyunsaturated fatty acids (LCPUFAs).
  • Suitable LCPUFAs include, but are not limited to, [alpha]-linoIeic acid, [gammaj-linoleic acid, linoleic acid, linolenic acid, eicosapentanoic acid (EPA), arachidonic acid (ARA) and/or docosahexaenoic acid (DHA).
  • Commercially available infant formula that contains DHA, ARA, or a combination thereof, for example, Enfamil® or LIPIL® may be supplemented with a composition or formulation described herein.
  • the weight ratio of ARA:DHA may be from about 1 :3 to about 9: 1 such as from about 1 :2 to about 4: 1 or about 2:3 to about 2: 1.
  • Suitable weight ratios of ARA:DHA include about 2: 1 , about 1 : 1 .5, about 1 : 1.3, about 1 : 1.9, about 1.5:, and about 1.47: 1.
  • the level of DHA may be in the range of about 0.0% and 1.00% of fatty acids, by weight.
  • the level of DHA may be about 0.32% by weight.
  • the level of DHA may be about 0.33% by weight.
  • the level of DHA may be about 0.64% by weight.
  • the level of DHA may be about 0.67% by weight.
  • the level of DHA may be about 0.96% by weight.
  • the level of DHA may be about 1.00% by weight.
  • the level of ARA is in the range of 0.0% and 0.67% of fatty acids, by weight.
  • the level of ARA may be about 0.67% by weight.
  • the level of ARA may be about 0.5% by weight.
  • the level of DHA may be in the range of about 0.47% and 0.48% by weight. If included, the effective amount of DHA may typically be from about 3 mg per kg of body weight per day to about 150 mg per kg of body weight per day.
  • Other suitable effective amounts of DHA include from about 6 mg per kg of body weight per day to about 100 mg per kg of body weight per day, from about 10 mg per kg of body weight per day to about 60 mg per kg of body weight per day, and from about 15 mg per kg of body weight per day to about 30 mg per kg of body weight per day.
  • the effective amount of ARA may typically be from about 5 mg per kg of body weight per day to about 150 mg per kg of body weight per day.
  • Other suitable amounts of ARA vary from about 10 mg per kg of body weight per day to about 120 mg per kg of body weight per day. Such as from about 15 mg per kg of body weight per day to about 90 mg per kg of body weight per day or from about 20 mg per kg of body weight per day to about 60 mg per kg of body weight per day.
  • the amount of DHA in the infant formula may vary from about 5 mg/100 kcal to about 80 mg/100 kcal such as from about 10 mg/100 kcal to about 50 mg/100 kcal or from about 15 mg/100 kcal to about 20 mg/100 kcal.
  • the amount of DHA may be about 17 mg/100 kcal. If an infant formula is utilized, the amount of ARA in the infant formula may vary from about 10 mg/100 kcal to about 100 mg/100 kcal such as from about 15 mg/100 kcal to about 70 mg/100 kcal or from about 20 mg/100 kcal to about 40 mg/100 kcal. The amount of ARA may be about 34 mg/100 kcal. If an infant formula is used, the infant formula may be supplemented with oils containing DHA and ARA using standard techniques known in the art. For example, DHA and ARA may be added to the formula by replacing an equivalent amount of an oil, such as high oleic sunflower oil, normally present in the formula.
  • an oil such as high oleic sunflower oil
  • the oils containing DHA and ARA may be added to the formula by replacing an equivalent amount of the rest of the overall fat blend normally present in the formula without DHA and ARA.
  • the source of DHA and ARA may be any source known in the art such as marine oil, fish oil, single cell oil, egg yolk lipid, and brain lipid.
  • the DHA and ARA are sourced from the single cell Martek oil, DHASCO(R), or variations thereof.
  • the DHA and ARA can be in natural form, provided that the remainder of the LCPUFA source does not result in any substantial deleterious effect on the infant.
  • the DHA and ARA can be used in refined form.
  • composition or formulation may include a LCPUFA source which contains EPA.
  • composition or formulation may include a LCPUFA source which is substantially free of EPA.
  • composition or formulation may be shelf stable.
  • shelf stable it is meant that the composition or formulation, in a form that is ready to consume, remains in a single homogenous phase (i.e., does not separate into more than one phase upon visual inspection), and/or that settling does not occur upon visual inspection after storage overnight in the refrigerator.
  • capsules, sachets and dry powder from fermented dairy
  • dry powder from fermented dairy
  • Vitamin A may be as Acetate or Palmitate, or in its pro-form Beta Carotene. Dose according to Recommended Dietary Allowances. For administration add contents to water, diluted fruit drink, milk, or malted milk drink, stirring rapidly until fully dispersed.
  • Vitamin A* (retinol) 2500-5000 IU
  • Vitamin A may be as Acetate or Palmitate, or in its pro-form Beta Carotene. Dose according to Recommended Dietary Allowances.
  • Microcrystalline cellulose for even dispersal
  • Vitamin A may be as Acetate or Palmitate, or in its pro-form Beta Carotene. Dose according to Recommended Dietary Allowances. For administration take one capsule daily.
  • Dairy products for example milks and yogurts
  • dairy products are a natural source of vitamin A (retinol).
  • vitamin A retinol
  • the Malted Milk may be fortified with additional vitamin A, other vitamins and fibre for example psyllium fibre.
  • Additional fermantative bacteria such as Lactobacillus delbrueckii subsp. bulgaricus and/or Streptococcus salivarius subsp. Thermophilus may be included in the formulation.
  • the fermentate or partial fermentate, enriched with B. infantis may then be dried to generate a powder (for example by spray drying or by other means known in the art).
  • the resulting powder is suitable for blending with a range of food products for example beverages, snack bars etc.
  • B. infantis 35624 has been previously shown to protect against inflammatory disease in a number of murine models (including colitis, arthritis, respiratory allergy and infection models).
  • Adoptive transfer of CD25+ T cells from B. infantis-fed animals to naive recipients transferred the anti-inflammatory protective effect.
  • consumption of this bacterium results in elevated IL-10 responses and Foxp3 expression.
  • Manipulation of T regulatory cell numbers or functions is an exciting therapeutic target in a wide range of inflammatory disorders. This data confirms our in vitro and murine models.
  • infantis 35624 induces the immune-regulatory enzyme RALDH2 in dendritic cells and the product of this enzyme, retinoic acid, was essential for the induction of regulatory T cells.
  • a formulation which combines the substrate, i.e. vitamin A or its derivatives, with a bacterial strain that induces expression of the enzyme responsible for substrate conversion will ensure the optimal conversion of the substrate to its immunologically active product.
  • This formulation will provide a profound therapeutic benefit in patients suffering from inflammatory disorders.
  • the formulation may be useful in maintaining a normal structure and function of the skin and mucous membranes (such as in the lung, intestines, nose, eyes and female reproductive tract).
  • the inflammatory disorder may be a mucosal inflammatory condition.
  • the inflammatory disorder may be associated with Mucosal/GI health such as diarrhoea, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), skin disorders such as acne, aging, beauty, respiratory inflammatory disorders (such as asthma and bronchopulmonary dysplasia), disorders of the eyes such as uveitis, disorders of the nose such as rhinitis or allergy or cancer associated with mucosal surfaces such as lung and GI.
  • the inflammatory disorder may be selected from one or more of: asthma, gastrointestinal inflammatory activity such as inflammatory bowel disease e.g.
  • vitamin A deficiency is estimated to affect approximately one third of children under the age of five around the world. It is estimated to claim the lives of 670,000 children under five annually. Deficiency of vitamin A severely affects vision and also reduces immunological defense and tolerance mechanisms.
  • treating means ameliorating, improving or remedying a disease, disorder, or symptom of a disease or condition.
  • reducing means to diminish in extent, amount, or degree.
  • preventing means to stop or hinder a disease, disorder, or symptom of a disease or condition through some action.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une formulation comprenant Bifidobacteria infantis 35624 dans une quantité pour induire l'expression de rétinaldéhyde déshydrogénase (RALDH) et un substrat qui fournit une source de rétinal qui est métabolisé en acide rétinoïque tout trans par RALDH. Le substrat peut être le rétinal, le rétinol, l'acétate de rétinyle, le palmitate de rétinyle, l'acétate de rétinol ou le palmitate de rétinol.
PCT/IE2012/000017 2011-04-11 2012-04-11 Formulation probiotique Ceased WO2012140636A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE20110173 2011-04-11
IE2011/0173 2011-04-11

Publications (1)

Publication Number Publication Date
WO2012140636A1 true WO2012140636A1 (fr) 2012-10-18

Family

ID=45999919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2012/000017 Ceased WO2012140636A1 (fr) 2011-04-11 2012-04-11 Formulation probiotique

Country Status (1)

Country Link
WO (1) WO2012140636A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141235A2 (fr) 1999-01-15 2001-10-10 Enterprise Ireland (trading as Bioresearch Ireland) Utilisation de (bifidobacterium) pour le traitement de maladies inflammatoires
WO2009100331A2 (fr) * 2008-02-06 2009-08-13 The Procter & Gamble Company Compositions, méthodes et kits de stimulation de la réponse immunitaire à une maladie respiratoire
WO2009144137A1 (fr) * 2008-05-27 2009-12-03 Nestec S.A. Probiotiques destinés à améliorer le microbiote intestinal
WO2010003803A1 (fr) 2008-07-08 2010-01-14 Nestec S.A. Composition nutritive contenant un mélange d'oligosaccharides
DE202010008308U1 (de) * 2010-08-18 2010-10-21 Rittinghausen, Reiner, Dr. Zusammensetzung zur nutritiven Ergänzung oder Behandlung bei Harnwegsinfekten und/oder bakteriellen Entzündungen der Schleimhäute

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141235A2 (fr) 1999-01-15 2001-10-10 Enterprise Ireland (trading as Bioresearch Ireland) Utilisation de (bifidobacterium) pour le traitement de maladies inflammatoires
EP1141235B1 (fr) * 1999-01-15 2006-05-17 Enterprise Ireland (trading as Bioresearch Ireland) Utilisation de (bifidobacterium) pour le traitement de maladies inflammatoires
US7195906B2 (en) 1999-01-15 2007-03-27 Enterprise Ireland (Trading As Bioresearch Ireland) Bifidobacterium in the treatment of inflammatory disease
WO2009100331A2 (fr) * 2008-02-06 2009-08-13 The Procter & Gamble Company Compositions, méthodes et kits de stimulation de la réponse immunitaire à une maladie respiratoire
WO2009144137A1 (fr) * 2008-05-27 2009-12-03 Nestec S.A. Probiotiques destinés à améliorer le microbiote intestinal
WO2010003803A1 (fr) 2008-07-08 2010-01-14 Nestec S.A. Composition nutritive contenant un mélange d'oligosaccharides
DE202010008308U1 (de) * 2010-08-18 2010-10-21 Rittinghausen, Reiner, Dr. Zusammensetzung zur nutritiven Ergänzung oder Behandlung bei Harnwegsinfekten und/oder bakteriellen Entzündungen der Schleimhäute

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
AKDIS M; AKDIS CA: "Therapeutic manipulation of immune tolerance in allergic disease", NAT REV DRUG DISCOV, vol. 8, 2009, pages 645 - 60
AKDIS M; BURGLER S; CRAMERI R ET AL.: "Interleukins, from I to 37, and interferon-gamma: Receptors, functions, and roles in diseases", J ALLERGY CLIN IMMUNOL, vol. 127, 2011, pages 701 - 21 E70
AKDIS M; VERHAGEN J; TAYLOR A ET AL.: "Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory I and T helper 2 cells", J EXP MED, vol. 199, 2004, pages 1567 - 75, XP055120575, DOI: doi:10.1084/jem.20032058
ATARASHI K; TANOUE T; SHIMA T ET AL.: "Induction of colonic regulatory T cells by indigenous Clostridium species", SCIENCE, vol. 331, 2011, pages 337 - 41, XP055178447, DOI: doi:10.1126/science.1198469
ATARASHI K; UMESAKI Y; HONDA K: "Microbiotal influence on T cell subset development", SEMIN IMMUNOL., vol. 23, 2011, pages 146 - 53, XP055005114, DOI: doi:10.1016/j.smim.2011.01.010
BRENNER DM; MOELLER MJ; CHEY WD; SCHOENFELD PS: "The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review", AM. J. GASTROENTEROL., vol. 104, no. 4, 2009, pages 1033 - 49, XP055032732, DOI: doi:10.1038/ajg.2009.25
COOMBES JL; SIDDIQUI KR; ARANCIBIA-CARCAMO CV ET AL.: "A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism", JEXP MED, vol. 204, 2007, pages 1757 - 64, XP055049227, DOI: doi:10.1084/jem.20070590
DARREN M BRENNER ET AL: "The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review", THE AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 104, no. 4, 10 March 2009 (2009-03-10), pages 1033 - 1049, XP055032732, ISSN: 0002-9270, DOI: 10.1038/ajg.2009.25 *
DI GIACINTO C; MARINARO M; SANCHEZ M ET AL.: "Probiotics ameliorate recurrent Thl- mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells", JIMMUNOL, vol. 174, 2005, pages 3237 - 46
DURIANCIK DM; LACKEY DE; HOAG KA: "Vitamin A as a regulator of antigen presenting cells", JNUTR, vol. 140, 2010, pages 1395 - 9
FUKATA M; ABREU MT: "Pathogen recognition receptors, cancer and inflammation in the gut", CURR OPIN PHARMACOL, vol. 9, 2009, pages 680 - 7, XP026766568, DOI: doi:10.1016/j.coph.2009.09.006
FUKUDA S; TOH H; HASE K ET AL.: "Bifidobacteria can protect from enteropathogenic infection through production of acetate", NATURE, vol. 469, 2011, pages 543 - 7, XP055008675, DOI: doi:10.1038/nature09646
GOUBIER A; DUBOIS B; GHEIT H ET AL.: "Plasmacytoid dendritic cells mediate oral tolerance", IMMUNITY, vol. 29, 2008, pages 464 - 75
HORI S; NOMURA T; SAKAGUCHI S: "Control of regulatory T cell development by the transcription factor Foxp3", SCIENCE, vol. 299, 2003, pages 1057 - 61, XP002430366, DOI: doi:10.1126/science.1079490
KARIMI K; INMAN MD; BIENENSTOCK J ET AL.: "Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice", AM J RESPIR CRIT CARE MED, vol. 179, 2009, pages 186 - 93, XP055005126, DOI: doi:10.1164/rccm.200806-951OC
LAI Y; DI NARDO A; NAKATSUJI T ET AL.: "Commensal bacteria regulate Toll-like receptor 3- dependent inflammation after skin injury", NAT MED, vol. 15, 2009, pages 1377 - 82
LEE YK; MAZMANIAN SK: "Has the microbiota played a critical role in the evolution of the adaptive immune system?", SCIENCE, vol. 330, 2010, pages 1768 - 73
LYONS A; O'MAHONY D; O'BRIEN F ET AL.: "Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models", CLIN EXP ALLERGY, vol. 40, 2010, pages 811 - 9
MANICASSAMY S; RAVINDRAN R; DENG J ET AL.: "Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity", NAT MED, vol. 15, 2009, pages 401 - 9
MARTÍNEZ-CAÑAVATE A; SIERRA S; LARA-VILLOSLADA F ET AL.: "A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy", PEDIATR ALLERGY IMMUNOL, vol. 20, 2009, pages 592 - 600
MASLOWSKI KM; MACKAY CR: "Diet, gut microbiota and immune responses", NAT IMMUNOL, vol. 12, 2011, pages 5 - 9
MAZMANIAN SK; LIU CH; TZIANABOS AO ET AL.: "An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system", CELL, vol. 122, 2005, pages 107 - 18
MCCARTHY J; O'MAHONY L; O'CALLAGHAN L ET AL.: "Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance", GUT, vol. 52, 2003, pages 975 - 80, XP002296949, DOI: doi:10.1136/gut.52.7.975
MIYARA M; SAKAGUCHI S.: "Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns", IMMUNOL CELL BIOL, vol. 89, 2011, pages 346 - 51
MURPHY CT ET AL., JOURNAL OFLEUKOCYTE BIOLOGY, vol. 88, December 2010 (2010-12-01)
O'HARA AM; O'REGAN P; FANNING A ET AL.: "Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius", IMMUNOLOGY, vol. 118, 2006, pages 202 - 15
O'HARA AM; SHANAHAN F: "The gut flora as a forgotten organ", EMBO REP, vol. 7, 2006, pages 688 - 93, XP055083032, DOI: doi:10.1038/sj.embor.7400731
O'MAHONY C; SCULLY P; O'MAHONY D ET AL.: "Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation", PLOS PATHOG, vol. 4, 2008, pages E 1000 112
O'MAHONY L; AKDIS M; CRAMERI R ET AL.: "Novel immunotherapeutic approaches for allergy and asthma", AUTOIMMUNITY, vol. 43, 2010, pages 493 - 503
O'MAHONY L; MCCARTHY J; KELLY P ET AL.: "Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles", GASTROENTEROLOGY, vol. 128, 2005, pages 541 - 51, XP005313721, DOI: doi:10.1053/j.gastro.2004.11.050
O'MAHONY L; O'CALLAGHAN L; MCCARTHY J ET AL.: "Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 290, 2006, pages 839 - 45
P. KONIECZNA ET AL: "Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells", GUT, vol. 61, no. 3, 3 November 2011 (2011-11-03), pages 354 - 366, XP055032736, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2011-300936 *
PALOMARES O; O'MAHONY L; AKDIS CA: "The many routes of dendritic cells to ensure immune regulation", JALLERGY CLIN IMMUNOL, vol. 127, 2011, pages 1541 - 2
PETER J. WHORWELL ET AL: "Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome", THE AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 101, no. 7, 1 July 2006 (2006-07-01), pages 1581 - 1590, XP055032761, ISSN: 0002-9270, DOI: 10.1111/j.1572-0241.2006.00734.x *
PRONIO A; MONTESANI C; BUTTERONI C ET AL.: "Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells", INFLAMM BOWEL DIS, vol. 14, 2008, pages 662 - 8, XP009147280
PULENDRAN B; TANG H; MANICASSAMY S.: "Programming dendritic cells to induce T(H)2 and tolerogenic responses", NAT IMMUNOL, vol. 11, 2010, pages 647 - 55
ROUND JL; LEE SM; LI J ET AL.: "The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota", SCIENCE, vol. 332, 2011, pages 974 - 7, XP055188763, DOI: doi:10.1126/science.1206095
ROUND JL; MAZMANIAN SK: "Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota", PROC NATL ACAD SCI U S A, vol. 107, 2010, pages 12204 - 9, XP055088747, DOI: doi:10.1073/pnas.0909122107
SAKAGUCHI S; MIYARA M; COSTANTINO CM ET AL.: "FOXP3+ regulatory T cells in the human immune system", NAT REV IMMUNOL, vol. 10, 2010, pages 490 - 500, XP002663981, DOI: doi:10.1038/nri2785
SHANAHAN F: "Gut microbes: from bugs to drugs", AM J GASTROENTEROL, vol. 105, 2010, pages 275 - 9
SIBARTIE S; O'HARA AM; RYAN J ET AL.: "Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria", BMC IMMUNOL, vol. 10, 2009, pages 54, XP021062295, DOI: doi:10.1186/1471-2172-10-54
SUN CM; HALL JA; BLANK RB ET AL.: "Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid", J EXP MED, vol. 204, 2007, pages 1775 - 85
VAN DER AAR AM; SIBIRYAK DS; BAKDASH G ET AL.: "Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells", JALLERGY CLIN IMMUNOL, vol. 127, 2011, pages 1532 - 40
VAN DER KLEIJ H; O'MAHONY C; SHANAHAN F ET AL.: "Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve", AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, vol. 295, 2008, pages 1131 - 7
WANG X; O'GORMAN MR; BU HF ET AL.: "Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/IOJ mice", JNUTR, vol. 139, 2009, pages 1595 - 602
WHORWELL PJ; ALTRINGER L; MOREL J ET AL.: "Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome", AM J GASTROENTEROL, vol. 101, 2006, pages 1581 - 90, XP055032761, DOI: doi:10.1111/j.1572-0241.2006.00734.x
YAMAZAKI S; STEINMAN RM: "Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells", JDERMATOL SCI, vol. 54, 2009, pages 69 - 75, XP026081229, DOI: doi:10.1016/j.jdermsci.2009.02.001

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains

Similar Documents

Publication Publication Date Title
WO2012140636A1 (fr) Formulation probiotique
Fernandez et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide
EP2323493B1 (fr) Probiotiques pour bébés
Thum et al. Can Nutritional Modulation of Maternal Intestinal Microbiota Influence the Development of the Infant Gastrointestinal Tract? 1, 2
Konieczna et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells
Rask et al. Differential effect on cell-mediated immunity in human volunteers after intake of different lactobacilli
EP2323494B1 (fr) Probiotiques pour bébés
Meng et al. Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults
Nagai et al. Fine-tuning of the mucosal barrier and metabolic systems using the diet-microbial metabolite axis
EP2658402A1 (fr) Combinaison symbiotique de probiotique et d'oligosaccharides de lait humain visant à favoriser la croissance d'un microbiote bénéfique
US11224651B2 (en) Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat allergies
JP2009529574A (ja) 誕生後に乳児に最良の始まりを与えるための難消化性糖類の使用
CN112911947B (zh) 包含2’岩藻糖基乳糖和膳食丁酸的营养组合物
US20220280581A1 (en) Beneficial bacteria and secretory immunoglobulin a
US20170360855A1 (en) Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
Marx Immunoprotective effects of probiotics in the elderly
Toghi et al. Bifidobacteria: A probable missing puzzle piece in the pathogenesis of multiple sclerosis
Blümer et al. Development of mucosal immune function in the intrauterine and early postnatal environment
WO2024184259A1 (fr) Composition comprenant la souche bifidobacterium animalis subsp. lactis et du 2'-fucosyllactose
US20190104759A1 (en) Nutritional compositions and their use
Binte Abu Bakar et al. Construction of a Synthetic Colostrum Substitute and Its Protection of Intestinal Cells against Inflammation in an In Vitro Model of Necrotizing Enterocolitis
EP3435787A1 (fr) Compositions nutritionnelles et leur utilisation
RU2804305C2 (ru) Пищевая композиция, содержащая мочевину и неперевариваемые олигосахариды
Hesser The Development of a Synbiotic Butyrate-Producing Bacterial Therapeutic for Food Allergy
WO2025233455A1 (fr) Composition nutritionnelle pour renforcer la barrière intestinale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12716645

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12716645

Country of ref document: EP

Kind code of ref document: A1